This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

30 May 2011

Novartis Announces Positive Results from ACZ885 Drug Studies

Novartis recently announced positive data from two late stage trials of its pipeline candidate ACZ885 for the treatment of patients suffering from severe gouty arthritis.

Novartis reported another positive pipeline development last week. The company announced positive results from the two pivotal Phase III studies of ACZ885 (canakinumab), a treatment for gouty arthritis.


The two Phase III, 12-week, randomised, multicentre, double-blind, double dummy and active-controlled studies included about 450 gouty arthritis patients and showed that the drug provided pain relief and reduced the risk of new attacks by up to 68% compared to an injectable steroid.


ACZ885 acts by targeting interleukin-1 beta, which is the cause of pain in gouty arthritis.


Professor Alexander So of the rheumatology departme

Related News